Speaker Profile
Ph.D., Assistant Professor, City of Hope
Biography
Dr. Nath is a cancer biologist with expertise in both experimental and computational biology. At City of Hope, Dr. Nath leads a collaborative research team that investigates the potential of AIML in enhancing cancer patient outcomes. Through the integration of bioinformatics and AIML tools, his research aims to unravel the underlying mechanisms of tumor progression and establish cutting-edge biomarkers for improving the clinical outcomes of patients with cancer. His research employs multi-omics approaches to identify the drivers of tumor evolution and the subsequent development of drug resistance. Dr. Nath aspires to translate research findings into clinical impact, notably contributing to upcoming clinical trials in lung and breast cancer that will implement novel AI-guided biomarkers. Dr. Nath currently is a principal investigator (PI) of an ARPA-H grant, an NIH U01 grant, a PHASE ONE foundation grant, a JKTG foundation grant, and co-investigator of an ARPA-H and California Institute for Regenerative Medicine (CIRM) grant.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
